Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
(2009) Annals of Oncology — Vol. 20, n° 7, p. 1275-1279 (2009)
Files
35509.pdf
Open Access - Adobe PDF
- 83.32 KB
Details
- Authors
- Abstract
- Patients and methods: In a multicentre phase II study, 32 patients with recurrent or metastatic HNSCC received 3-AP Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), an inhibitor of ribonucleotide reductase, 96 mg/m(2), daily for 4 days every 14 days (one cycle). Eligibility criteria required Eastern Cooperative Oncology Group performance status (ECOG PS) of zero to two with a life expectancy of > 3 months; one prior chemotherapy regimen was allowed. Results: Thirty patients were assessable for response and toxicity. Median age was 57 years (range 36-79) and median ECOG PS was one (range 0-2). Thirteen patients had previously been treated with chemotherapy. A total of 130 cycles were administered with a median number of cycles of 3.5 (range 1-8). Mild anaemia (40%), nausea (22%) and fatigue (22%) were commonly reported with G3 and G4 neutropenia documented in 22% and 22%, respectively. Overall response rate was 5.9% (95% confidence interval 0.2% to 28.7%). One patient achieved a partial response, eight had stable disease and 21 progressive disease. Median time to disease progression was 3.9 months. Conclusions: 3-AP Triapine as a single agent, at this dose and schedule, is well tolerated but has only minor activity in the treatment of advanced HNSCC.
- Affiliations
Citations
Nutting, C. M., van Herpen, C. M. L., Miah, A. B., Bhide, S. A., Machiels, J.-P., Buter, J., Kelly, C., de Raucourt, D., & Harrington, K. J. (2009). Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 20(7), 1275-1279. https://doi.org/10.1093/annonc/mdn775 (Original work published 2009)